IL17A and cancer: In contrast, for poorly differentiated (G3) tumors, IL-17A levels remained consistently lower and showed a steeper, continuous decline with increasing IL-8, indicating an attenuated or dysregulated inflammatory response characteristic of more aggressive cancers.